AMAG Pharmaceuticals
AMAG
AMAG was delisted on the 13th of November, 2020.
97 hedge funds and large institutions have $449M invested in AMAG Pharmaceuticals in 2013 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 38 increasing their positions, 33 reducing their positions, and 7 closing their positions.
64% more call options, than puts
Call options by funds: $934K | Put options by funds: $571K
29% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 7
15% more repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 33
1.27% more ownership
Funds ownership: 94.33% → 95.59% (+1.3%)
1% more funds holding
Funds holding: 96 → 97 (+1)
1% less capital invested
Capital invested by funds: $455M → $449M (-$6.54M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CM
Castleark Management
Chicago,
Illinois
|
+$5.23M |
| 2 |
CCM
Consonance Capital Management
New York
|
+$4.86M |
| 3 |
Morgan Stanley
New York
|
+$4.78M |
| 4 |
State Street
Boston,
Massachusetts
|
+$4.08M |
| 5 |
NI
Numeric Investors
Boston,
Massachusetts
|
+$3.15M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$6.82M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$4.3M |
| 3 |
CII
CR Intrinsic Investors
Stamford,
Connecticut
|
-$2.39M |
| 4 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
-$1.98M |
| 5 |
BIM
Bogle Investment Management
Newton Lower Falls,
Massachusetts
|
-$1.97M |
AMAG Hedge Fund Activity: Q3 2013 in Review
97 of the 3,096 institutional investors tracked by Wall St. Rank reported a position in AMAG Pharmaceuticals (AMAG) for Q3 2013, worth a combined $449M — down 1.4% from $455M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new AMAG positions and 7 closed out — a net gain of 2 holders — while 38 added to existing stakes and 33 trimmed.
The largest buyer was Castleark Management, opening a new position worth an estimated $5.23M. The largest seller was Adage Capital Partners, cutting an estimated $6.82M.
- 97 institutional investors held AMAG Pharmaceuticals (AMAG) as of Q3 2013, up from 96 in Q2 2013.
- Funds reported $449M of AMAG Pharmaceuticals stock for Q3 2013, down 1.4% quarter-over-quarter.
- 9 funds opened new AMAG Pharmaceuticals positions in Q3 2013 and 7 closed out, a net change of +2 holders.
- The largest AMAG Pharmaceuticals buyer in Q3 2013 was Castleark Management, an estimated $5.23M added.
- The largest AMAG Pharmaceuticals seller in Q3 2013 was Adage Capital Partners, an estimated $6.82M sold.
Based on aggregated 13F filings for Q3 2013.